Organon Entered into an Agreement with Henlius to Commercialize Perjeta (pertuzumab) and Prolia/Xgeva (denosumab) Biosimilars
Shots:
- Henlius to receive $73M upfront & is eligible to receive an additional fee of $30M upon achievement of development, regulatory & commercial milestones & will lead the development & commercialization activities of the products if approved
- Organon gets the commercialization rights for biosimilar candidates referencing Perjeta and Prolia/Xgeva (Ex- China including Hong Kong, Macau & Taiwan) for breast cancer & osteoporosis
- Organon has an exclusive license option for global commercialization rights for a biosimilar candidate referencing Yervoy (ipilimumab, HLX13). The collaboration will expand the biosimilars portfolio & focus on women’s health with biosimilar candidates for osteoporosis & breast cancer
Ref: Bussinesswire | Image: Organon
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
